Mursla is dedicating resources to help improve covid-19 therapeutics & diagnostics solutions.
We are currently coordinating a consortium capitalising upon our expertise in exosome-based medical applications & nanobiotech technologies.
It is focused on developing stem cell-derived exosome therapy for covid-19 hospitalized patients exhibiting life-threatening Acute Respiratory Distress Syndrome (ARDS) and/or for covid-19 recovered patients suffering from heavily impaired lungs.
We are disseminating less-known tech & bio facts on the situation (e.g. diagnostics tools, link between exosomes & viruses) via social media.
We hope to be as helpful as possible to our community during those difficult times.